BioSpace News Archive

Seeking to address estimates that more than a third of COVID-19 deaths nationally have occurred in nursing homes and long-term care facilities—more than 38,000 – the American Medical Directors Association published recommendations for reducing the spread of the pandemic virus among residents and staff.

Amedisys, Inc. (NASDAQ: AMED), one of America’s leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer will present at the 40 th Annual William Blair Growth Stock Conference on Wednesday, June 10, 2020. The presentation will begin at 3:00 p.m. Eastern Time. To access a live webcast of the Amedisys presentation, please log on through our website at http://inv

- COVIDTRAPTM, a proprietary ACE2-Fc decoy protein, binds strongly to the spike protein of the SARS-CoV-2 virus; - COVIDTRAP neutralizes the SARS-CoV-2 virus and prevents infection in African green monkey kidney epithelial cells (VERO/E6 cells) in vitro at low concentration; - STI-4398 has received FDA Feedback on the rapid development of the product candidate; and - Together with Sorrento’s previously announced potent STI-1499 neutralizing antibody preclinical prod

Health & Wellness Partners, LLC (HWP), a global medical communications company, was named as a 2020 Forbes Small Giant.

The Company’s Proposed Pharmaceutical Grade Version of Tauri-Gum™ is Being Developed for Nausea Regulation, Intended Specifically to Target: Patients Subjected to Ongoing Chemotherapy Treatment(s) (the “Indication”) NEW YORK, NY, June 05, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences Company, with proprietary CBD & CBG infused chewing gums and edibles product(s) as well as two

DLA Piper represented advised NuVasive, Inc. (NASDAQ: NUVA), a San Diego -based medical device company that creates and distributes products for surgical treatment of spine disorders, in its offering of US$400 million aggregate principal amount of 1.00% convertible senior notes due 2023. NuVasive also granted to the initial purchasers of

BioMarker Strategies, LLC today announced the promotion of Greg Bertenshaw. Ph.D., to the position of Chief Operating and Science Officer, effective immediately. Dr. Bertenshaw, formerly Vice President, Research & Development, will continue to report directly to Jerry Parrott, President and Chief Executive Officer. This press release features multimed

June 5, 2020 15:24 UTC Industry-leading CME provider hosts an interactive webcast series that shares comprehensive in-depth analysis and updates from the Annual Oncology Meeting CRANBURY, N.J.--( BUSINESS WIRE )-- As the Annual Oncology Meeting transitions to a virtual program, Physicians’ Education Resource® (PER®) launched “Oncology NOW,” a series of free accredited live and interactive webcasts that delivers expert insights, deeper analysis, and critical updates on a

Celerion announced today the expansion of specialized high-resolution mass spectrometry (HR-MS) profiling capabilities demonstrating their commitment to further assisting sponsors in meeting the regulatory requirements to characterize and quantify drug metabolites and their potential for impacting drug effect as part of the process to becoming an approved therapeutic product. Celerion has created a compelling bioanalytical

Retractable Technologies, Inc. (NYSE American: RVP) (the “Company”) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic, and related health and travel concerns, the adjourned 2020 annual meeting of shareholders of Retractable Technologies, Inc. (the “Annual Meeting”) has been changed to a virtual-only format via live webcast. As previously announced, the Annual Meeting will be he